In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Merck KGAA’s Big Second Bet On Cancer

Executive Summary

Andree Blaukat, Merck KGAA's SVP and head of the Translational Innovation Platform Oncology, discusses the company's DNA repair pipeline.

You may also be interested in...



Gates MRI CEO Penny Heaton Speaks …

Insights from Gates Medical Research Institute CEO Dr. Penny Heaton. 

Gates Foundation Plots A Fresh Metric For Market Access: Lives Saved

In Vivo visits Gates Medical Research Institute CEO Dr. Penny Heaton to review its first pipeline of drugs and vaccines to attack four of the world’s biggest killers: TB, malaria, enteric diseases and other conditions affecting maternal, newborn and child health.

Market Access 2020: Understanding US Payer Expectations

Big pharma is facing a difficult US competitive landscape as its traditional customers realign to build their own redoubts of size, scale and reach.

Topics

Related Companies

Related Deals

UsernamePublicRestriction

Register

IV005240

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel